Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 13.9% - Here's What Happened

Key Points

• Shares of Armata Pharmaceuticals jumped 13.9% to about $14.23 after analysts including HC Wainwright and JonesTrading issued Buy ratings and a consensus price target of $15.
• The company reported a large quarterly loss of ($3.42) per share (missing the -$0.19 estimate) on revenue of $1.09M, has a market cap of about $538M, and is a clinical‑stage biotech developing bacteriophage therapies for antibiotic‑resistant infections.
• Several hedge funds—including Renaissance Technologies, State Street and Goldman Sachs—added or initiated positions in the fourth quarter, with institutional ownership around 3.57%.

Shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) shot up 13.9% on Tuesday . The company traded as high as $14.00 and last traded at $14.2320. 48,663 shares traded hands during mid-day trading, a decline of 0% from the average session volume of 48,719 shares. The stock had previously closed at $12.50.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ARMP. HC Wainwright raised their target price on Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a "buy" rating in a report on Monday, February 23rd. JonesTrading initiated coverage on Armata Pharmaceuticals in a research report on Monday, January 5th. They issued a "buy" rating and a $15.00 target price for the company. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $15.00.

Armata Pharmaceuticals Stock Up 17.5%

The firm has a market capitalization of $538.06 million, a PE ratio of -3.03 and a beta of 1.38. The stock has a 50-day simple moving average of $10.12 and a 200-day simple moving average of $7.41.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($3.23). The firm had revenue of $1.09 million during the quarter, compared to the consensus estimate of $0.74 million.

Hedge Funds Weigh In On Armata Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. 683 Capital Management LLC purchased a new position in shares of Armata Pharmaceuticals in the fourth quarter valued at $878,000. Geode Capital Management LLC grew its position in shares of Armata Pharmaceuticals by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company's stock valued at $690,000 after purchasing an additional 5,342 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Armata Pharmaceuticals by 65.9% in the fourth quarter. Renaissance Technologies LLC now owns 68,496 shares of the company's stock valued at $430,000 after purchasing an additional 27,200 shares in the last quarter. State Street Corp grew its position in shares of Armata Pharmaceuticals by 26.1% in the fourth quarter. State Street Corp now owns 50,800 shares of the company's stock valued at $319,000 after purchasing an additional 10,500 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Armata Pharmaceuticals in the fourth quarter valued at $284,000. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company's proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata's pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.